EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Biomarkers in Autism Spectrum Disorder: From Traditional Constraints to AI-Driven Horizons in Precision Medicine

Berkan Şahin, Cansu Çobanoğlu Osmanlı

European Journal of Therapeutics · 27.11.2025 · 31 (6) · 463-476

DOI: 10.58600/eurjther2832 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Therapeutics, online erschienen am 27.11.2025. Verfasst von Berkan Şahin und 1 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The aim of this review is to comprehensively evaluate the potential of biomarkers in the diagnosis, prognosis, and individualized treatment of Autism Spectrum Disorder (ASD), considering its complex nature and current diagnostic limitations.

Methods

The article provides an updated literature review focusing on blood- and urine-based biomarkers (oxidative stress, inflammation, neurotransmitters, microbiome), neuroimaging, genetic, and physiological markers. It also examines key challenges, ethical considerations, and promising future directions such as artificial intelligence (AI)-assisted multi-omics data integration.

Results

Biomarkers measured in blood and urine (e.g., isoprostanes, 8-OHdG, and inflammatory cytokines) highlight the role of oxidative stress and chronic inflammation in ASD pathophysiology. Neuroimaging and genetic markers show promise for early risk identification and biological subtyping. However, most current studies suffer from small sample sizes, replication issues, and lack of standardization, limiting their clinical applicability.

Conclusion

Biomarker-based approaches hold promise for making ASD diagnosis more objective and for facilitating earlier intervention by reducing diagnostic delays. In the future, AI-driven multi-omics integration may provide deeper insights into ASD heterogeneity and support the development of personalized treatment strategies. Managing ethical concerns such as privacy and discrimination through a neurodiversity-oriented perspective will be crucial in this process.

Zitieren

APA

Şahin, B., & Osmanlı, C. Ç. (2025). Biomarkers in Autism Spectrum Disorder: From Traditional Constraints to AI-Driven Horizons in Precision Medicine. European Journal of Therapeutics, 31(6), 463-476. https://doi.org/10.58600/eurjther2832

Vancouver

Şahin B, Osmanlı CÇ. Biomarkers in Autism Spectrum Disorder: From Traditional Constraints to AI-Driven Horizons in Precision Medicine. European Journal of Therapeutics. 2025;31(6):463-476. doi:10.58600/eurjther2832

BibTeX
@article{ahin2025,
  author = {Şahin, Berkan and Osmanlı, Cansu Çobanoğlu},
  title = {Biomarkers in Autism Spectrum Disorder: From Traditional Constraints to AI-Driven Horizons in Precision Medicine},
  journal = {European Journal of Therapeutics},
  year = {2025},
  volume = {31},
  number = {6},
  pages = {463--476},
  doi = {10.58600/eurjther2832}
}
Kostenlos starten →